The results of this study will help guide Skye’s development activities within the heterogeneous obesity market.

  1. Amir H. Sam, Victoria Salem, and Mohammad A. Ghatei. Rimonabant: From RIO to Ban. Journal of Obesity. 2011
  2. Van Gaal et al., Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients. Diabetes Care, Vol. 31, SUPPLEMENT 2, FEB 2008
  3. Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity. New Eng J Med, 384;11, 2021
  4. Amir H. Sam, Victoria Salem, and Mohammad A. Ghatei. Rimonabant: From RIO to Ban. Journal of Obesity. 2011